News Search Year - Any - 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 2008 Archive February 19, 2020 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Archive February 13, 2020 Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock Archive February 12, 2020 Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock Archive February 12, 2020 Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Archive January 13, 2020 Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones Archive January 6, 2020 Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference Archive December 16, 2019 Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Archive December 4, 2019 Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors Archive November 26, 2019 Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman Archive November 13, 2019 Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting
Archive February 19, 2020 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
Archive February 13, 2020 Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Archive February 12, 2020 Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Archive February 12, 2020 Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Archive January 13, 2020 Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones
Archive January 6, 2020 Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
Archive December 16, 2019 Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Archive December 4, 2019 Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors
Archive November 26, 2019 Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman
Archive November 13, 2019 Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting
